Track Virax Biolabs Group Limited Ordinary Shares — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Virax Biolabs Group Limited Ordinary Shares VRAX · Stock Open Virax Biolabs Group Limited Ordinary Shares in new tab

2.31 USD
Add to portfolio
EPS
-12.59
P/B
0.20
ROE
-78.65
Beta
1.36
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateDec. 2, 2026
EPS-12.59
Book Value13.08
Price to Book0.20
Debt/Equity5.65
% Insiders1.579%
Growth
Revenue Growth6.85%
Estimates
Forward P/E-0.43
Forward EPS-6.00

DCF Valuation

Tweak assumptions to recompute fair value for Virax Biolabs Group Limited Ordinary Shares (VRAX)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Virax Biolabs Group Limited Ordinary Shares Logo Virax Biolabs Group Limited Ordinary Shares Analysis (VRAX)

United Kingdom Health Care Official Website Stock

Is Virax Biolabs Group Limited Ordinary Shares a good investment? Virax Biolabs Group Limited Ordinary Shares (VRAX) is currently trading at 2.31 USD.

Earnings Schedule: Virax Biolabs Group Limited Ordinary Shares is expected to release its next earnings report on Dec. 2, 2026. The market consensus estimate for Forward EPS is -6.00.

Investor FAQ

Does Virax Biolabs Group Limited Ordinary Shares pay a dividend?

No, it does not currently pay a dividend.

What asset class is Virax Biolabs Group Limited Ordinary Shares?

Virax Biolabs Group Limited Ordinary Shares is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Dec. 2, 2026. The company currently has a trailing EPS of -12.59.

Company Profile

Virax Biolabs Group Limited, a biotechnology company, focuses on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated diseases in the United Kingdom, the United States, and China. The company offers ViraxImmune, a T cell-based immune profiling and diagnostic platform for post-acute infection syndromes, including long COVID, myalgic encephalomyelitis / chronic fatigue syndrome, and post-treatment Lyme disease. It also provides ImmuneSelect, a research-use-only portfolio of peptide pool ELISpot plates and related immune reagents. In addition, the company is involved in research and development activities and the provision of procurement, warehousing, product development, and staffing management services. It serves research organizations, academic institutions, contract research organizations, biopharmaceutical companies, independent laboratories, and distributors. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was founded in 2013 and is headquartered in Lanarkshire, United Kingdom.

Exchange Ticker
NMS (United States) VRAX
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Dec. 18, 2023 1:10
June 26, 2026 1:25
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion